| Document |
Document Title |
|
WO/2024/068153A1 |
This application relates generally to the field of treatment or prevention of "open" vascular surgical interventions with administration of a macrocyclic triene immunosuppressive compound in order to reduce or eliminate stenotic and/or v...
|
|
WO/2024/067500A1 |
Provided is an antisense nucleic acid glycosyl conjugate, which is formed by covalently conjugating a sugar molecule to the 5' end of an antisense nucleic acid by means of a linker arm. In-vitro pharmacodynamics show that the anti-tumor ...
|
|
WO/2024/073680A1 |
Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of neurodegenerative disorders and diseases mediated by soluble epoxide hydrolase.
|
|
WO/2024/068159A1 |
This application relates generally to the field of synthesis, formulations and perivascular treatment methods involving cyclic ester derivatives of everolimus.
|
|
WO/2024/072075A1 |
The present invention relates to a pharmaceutical composition for preventing and treating cancers, including lung cancer, caused by abnormal cell growth, the composition containing, as active ingredients, a novel trisubstituted pyrimidin...
|
|
WO/2024/066080A1 |
An arsenic compound-based tumor vaccine, a preparation method therefor, and an application thereof. The arsenic compound-based tumor vaccine comprises tumor cells treated by an arsenic compound, may activate an anti-tumor immune response...
|
|
WO/2024/073709A2 |
The technology described herein relates modified oligonucleotides and double-stranded RNAs, e.g., siRNAs, compositions and kits comprising them and methods of their use for inhibiting target genes.
|
|
WO/2024/070172A1 |
Provided are an exceptional agent and method for inducing differentiation from dental pulp cells into odontoblasts. Also provided are an exceptional pharmaceutical composition and pulp capping agent for dentin regeneration. This agent fo...
|
|
WO/2019/043596A9 |
The present invention relates to compositions providing improved substantivity, comfort and/or feel to the eye upon application. The present invention further relates to compositions comprising a cellulose derivative in combination with ...
|
|
WO/2024/073056A1 |
A pharmaceutical formulation for treating a patient with an elevated serum level of an intestinal microbial metabolite includes an effective amount of cucurbituril. A method of treating a patient with an elevated serum level of an intest...
|
|
WO/2024/067820A1 |
Provided are novel tricyclic compounds as CDK inhibitors, which are useful for treating diseases or conditions mediated by CDKs, particularly cancers and other diseases caused by abnormal cell proliferation. Preparation methods, pharmace...
|
|
WO/2024/067812A1 |
The present invention relates to an aromatic acetylene derivative, a preparation method therefor, and a medical use of a pharmaceutical composition containing said derivative. Specifically, the present invention relates to an aromatic ac...
|
|
WO/2024/073672A1 |
The present disclosure relates to methods of treating a kidney disease or disorder, including methods comprising administering sparsentan and a SGLT2 inhibitor to a subject in need thereof.
|
|
WO/2024/073114A1 |
The present disclosure relates to compositions of matter and methods used to activate effector nucleic acids and effector targets in vivo via a CRISPR-based cascade system. The compositions and methods achieve non-specific delivery of ca...
|
|
WO/2024/067631A1 |
Use of a composition of an FAK inhibitor, a substance for inducing immunogenic cell death, and an immune checkpoint inhibitor in preparing a drug for treating a tumor. The substance for inducing immunogenic cell death is an RNA polymeras...
|
|
WO/2024/069144A1 |
The invention provides means and methods for treating, preventing or reversing retinal degeneration by RNA editing. The methods comprise administering to the subject a vector or a pair of complementary vectors that express a dCaslS-ADARn...
|
|
WO/2024/068758A1 |
The present invention relates to an orodispersible formulation of vortioxetine comprising a granular component comprising vortioxetine or a salt thereof together with an inert carrier; a polymeric component; and an extragranular matrix w...
|
|
WO/2024/072793A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
|
WO/2024/068699A1 |
This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro-particles of the anti-TB compound bedaquiline, suspended in an aqueous pharmaceutically acceptable carri...
|
|
WO/2024/067542A1 |
The present invention relates to a spirocyclic derivative-containing salt or crystal form, and a preparation method therefor and a use thereof. Particularly, the present invention relates to a salt or crystal form of a compound (R)-1-(4'...
|
|
WO/2024/071720A1 |
The present invention relates to a pharmaceutical composition for preventing or treating periodontitis, and an anti-inflammatory composition, the compositions comprising lipoteichoic acid or a pharmaceutically acceptable salt thereof. Th...
|
|
WO/2024/069589A1 |
Hexahydrocannabinol (HHC), hexahydrocannabidiol (H4CBD), and hexahydrocannabidivarin (H4CBDV) derivatives are disclosed. Also disclosed are pharmaceutical compositions comprising such derivatives. Further described are methods of use the...
|
|
WO/2024/069644A1 |
The present invention relates to a pharmaceutical acceptable ferric carboxymaltose with better characterisation for bio-available iron and process for preparation thereof. The process comprises a controlled oxidation step to minimize ran...
|
|
WO/2024/067330A1 |
Provided is use of a pentacyclic triterpenoid compound in preparing a medicament for preventing and/or treating sarcoidosis. The pentacyclic triterpenoid compound has the advantages of causing small liver and kidney damage, being safe to...
|
|
WO/2024/067584A1 |
A complex, comprising 3-hydroxybutyric acid and sodium 3-hydroxybutyrate. The 3-hydroxybutyric acid and sodium 3-hydroxybutyrate are in a ratio of 1: 10 to 10: 1. The preparation method therefor comprises: (1) obtaining substance A by me...
|
|
WO/2024/073283A1 |
Disclosed herein are amino bicyclic nitrogen heterocyclic ring system compounds which inhibit nuclear receptor-binding SET domain proteins (NSD's), such as 6-amino-9H-purin-9-yl, 8-amino imidazo[1,2-a]pyrazin-3-yl, imidazo[2,1-f][1,2,4]t...
|
|
WO/2024/067433A1 |
The present invention describes a novel molecule with inhibitory activity against protein arginine methyltransferase 5 and methods for synthesis and use of the compound. Specifically, the present invention describes a compound of formula...
|
|
WO/2024/067660A1 |
The present disclosure relates to an aza-fused ring compound, a preparation method therefor, and a use thereof in medicine. Specifically, the present disclosure relates to an aza-fused ring compound represented by general formula (I), a ...
|
|
WO/2024/073507A1 |
Described herein are macrocyclic compounds of Formulas (Al), (BI), and (CI) which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a com...
|
|
WO/2024/071629A1 |
The present invention relates to a novel fluorene derivative compound, and a use thereof in the prevention or treatment of metabolic diseases and/or cancer diseases through the action thereof as a PDK4 inhibitor.
|
|
WO/2024/065900A1 |
An siRNA for inhibiting tumor growth and a use thereof. The siRNA targets an mRNA fragment encoded by a sequence shown in SEQ ID NO: 45 or SEQ ID NO: 46. A method for using the siRNA to inhibit tumor growth.
|
|
WO/2024/067560A1 |
Disclosed in the present invention are a sulfonamide compound and the medical use thereof as a STING inhibitor, specifically, a compound as represented by formula (I) or a pharmaceutically acceptable salt or ester or solvate thereof, whi...
|
|
WO/2024/067463A1 |
Provided are a compound of formula (I) or a pharmaceutically acceptable salt, ester, optical isomer, tautomer, stereoisomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite, chelate, complex, inclusion compound or prodr...
|
|
WO/2024/071398A1 |
The purpose of the present invention is to provide a drug for the prevention and/or treatment of diseases associated with ABHD6, said drug containing a compound having ABHD6 inhibitory activity as an active ingredient. A compound represe...
|
|
WO/2024/068524A1 |
The present invention relates to methods for treating bacterial prostatitis, which comprises administration of gepotidacin or pharmaceutically acceptable salts thereof to a human in need thereof.
|
|
WO/2024/073628A1 |
The subject invention pertains to compositions comprising an opioid receptor antagonist and an opioid receptor agonist and methods of inhibiting an opioid overdose in a subject. The opioid receptor antagonist can be naloxone or a derivat...
|
|
WO/2024/073587A1 |
Compounds and methods for inhibiting Nrf2 by activating KEAP1.
|
|
WO/2024/065243A1 |
Provided herein is an application of an anti-PS antibody in combination with docetaxel and/or paclitaxel in a drug for the treatment of a breast cancer, belonging to the technical field of drugs. By means of the combination of the anti-P...
|
|
WO/2024/073735A2 |
Provided herein are oligonucleotides (e.g., siRNA) targeting S6K1. Also provided are methods of treating a disease associated with S6K1 expression.
|
|
WO/2024/067691A1 |
Disclosed are a nitrogen-containing heterocyclic compound and pharmaceutical use thereof. Specifically, disclosed are a nitrogen-containing heterocyclic compound represented by general formula (I), a preparation method therefor, a pharma...
|
|
WO/2024/069634A1 |
The present invention is directed to compounds and compositions comprising thereof. Further, methods of use such as for the treatment and prevention of cancer in a subject in need thereof are also provided.
|
|
WO/2024/066734A1 |
The present invention relates to a high-stability alfacalcidol liquid oral formulation and a preparation method therefor. Each 100 mL of the liquid oral formulation comprises the following raw materials by weight: less than or equal to 0...
|
|
WO/2024/069574A1 |
The present disclosure encompasses solid state forms of Denifanstat, in embodiments crystalline polymorphs of Denifanstat, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2024/073673A1 |
The present disclosure provides lipid compounds useful in treating inflammatory skin diseases.
|
|
WO/2024/073752A2 |
Dosage regimens for gastric residence systems comprising risperidone or a salt thereof are disclosed. The dosage regimens include regimens where immediate release risperidone or a salt thereof is administered during a first period, immed...
|
|
WO/2024/067729A1 |
Disclosed herein are an S-ketamine transdermal composition and a preparation method therefor and use thereof. The transdermal composition comprises S-ketamine or a pharmaceutically acceptable salt thereof, an acrylate pressure-sensitive ...
|
|
WO/2024/071099A1 |
The present invention addresses the problem of providing a novel nucleic acid molecule capable of simultaneously achieving both a high gene regulatory effect and toxicity reduction.　Provided is a nucleic acid molecule that contains a b...
|
|
WO/2024/071319A1 |
The present disclosure provides a composition comprising a glycolytic intermediate metabolite or a salt thereof, preferably, phosphoenolpyruvate (PEP), glucose-6-phosphate (G6P), fructose-6-phosphate (F6P), or 3-phosphoglycerate (3PG), o...
|
|
WO/2024/072907A1 |
Apelin receptor modulators can improve physical performance, slow progression of age-related frailty, and can reduce age-related muscle weakness in human patients. This disclosure provides methods for treating muscle conditions using a p...
|
|
WO/2024/069423A1 |
Ingestion of therapeutic agents are characterized by low bioavailability, a lengthy onset of action, and inconsistent absorption. The present disclosure provides a therapeutic formulation for pulmonary or sublingual administration of an ...
|
